Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 2 1

Status

Terminated 2Recruiting 1Completed 1

Sponsor Class

OTHER 4

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Gastrointestinal 31Thoracic 26Genitourinary 14Breast 12Lymphoid 8Head & Neck 7Gynecologic 5Dermatologic 4Other solid neoplasm 3Other hematologic neoplasm 2NET 2Endocrine 2Sarcoma 1Classical hematology 1CNS 1

Conditions

Melanoma 4

Interventions

pembrolizumab 339Nivolumab 305Ipilimumab 274Cyclophosphamide 195aldesleukin 148Interleukin-2 110fludarabine phosphate 107trametinib 85Temozolomide 83fludarabine 81Dacarbazine 81dabrafenib 77Radiotherapy 75Biopsy 75Vemurafenib 71Imiquimod 53Bevacizumab 51sargramostim 50Magnetic Resonance Spectroscopy 50Specimen Handling 49Radiosurgery 49Peripheral Blood Stem Cell Transplantation 49Paclitaxel 49Aminolevulinic Acid 49binimetinib 48Carboplatin 48Blood Specimen Collection 47cemiplimab 46Cisplatin 453-ingenyl angelate 45

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Tomography, X-Ray Computed × Dermatologic × Clear all
NCT06199713 2026-01-20

Correlating Early FDG PET/CT and ctDNA in Immune Checkpoint Inhibitor (ICI)-Treated Melanoma Patients

University of Wisconsin, Madison

Recruiting
24 enrolled
Dermatologic

Melanoma

NCT02922283 2024-05-06

IL2 Imaging in Metastatic Melanoma

University Medical Center Groningen

Phase NA Terminated
19 enrolled
Dermatologic

Melanoma

NCT03089606 2023-11-15

Pembrolizumab TX-naive Distant Mets Melanoma and Use of (C11-AMT) PET at Baseline as Imaging Biomarker

UNC Lineberger Comprehensive Cancer Center

Phase 2 Completed
27 enrolled 14 charts
Dermatologic

Melanoma

NCT02236546 2017-04-13

FDG-PET in Advanced Melanoma

Vanderbilt-Ingram Cancer Center

Phase NA Terminated
3 enrolled 4 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡